Texas Biotech (TXB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: timmask who wrote (115)	3/15/1997 12:24:00 AM
From: Bharat H. Barai	of 834

I think so. It gives great leverage at small cost. The exercise price is $ 8.44, by Dec. 21, 1998. Once the stock goes over $10.44 (assuming you purchased the warrant at $ 2.0), all price over $ 10.44 is your profit, Dollar per Dollar, plus time premium. Some data on Argatroban (Novastan) will be published at the American College of Cardiology meeting, starting March 17, 1997. Additional data may be published in few weeks after that. It is expected that Texas Biotech will file for NDA (New Drug Application)early this summer and the drug should get approval in fall. All these news events and approval process will push up stock price. The drug will go in clinical use in winter this year or early next year, further boosting the stock. How much up ? we can all guess ! In my mind, there is little doubt that the drug will be approved this year. It is a new drug for US market but not in world market. It is an invention of Mitsubishi Chemicals, Japan and is already in use in Japan for last 2-3 years. So there are no surprises likely. Bharat Barai MD Hematologist

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next